SECTOR : Biotech
ENTRY DATE : 2022
BUSINESS: Venture Capital
WEB : www.domaintherapeutics.com/
Domain Therapeutics, a biopharmaceutical company operating in France and Canada, is dedicated to the discovery and development of new drug candidates targeting G Protein-Coupled Receptors (GPCRs), one of the most important classes of drug targets. The company focuses on developing high-value drug candidates to tackle GPCR-mediated immunosuppression in immune-oncology.
PRESSE RELEASE(S) :
10/05/2022 • Domain Therapeutics raises $42m Series A financing